Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review

The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding adverse event (AE) reporting in randomized clinical trials (RCTs). Limited data exist regarding adherence to these guidelines in publications...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 31; no. 31; p. 3957
Main Authors: Péron, Julien, Maillet, Denis, Gan, Hui K, Chen, Eric X, You, Benoit
Format: Journal Article
Language:English
Published: United States 01.11.2013
Subjects:
Antineoplastic Agents - adverse effects
Clinical Trials, Phase III as Topic
Drug-Related Side Effects and Adverse Reactions
Guideline Adherence - standards
Guideline Adherence - statistics & numerical data
Guidelines as Topic
Humans
Neoplasms - drug therapy
Randomized Controlled Trials as Topic - standards
ISSN:1527-7755, 1527-7755
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding adverse event (AE) reporting in randomized clinical trials (RCTs). Limited data exist regarding adherence to these guidelines in publications of oncology RCTs. All phase III RCTs published between 2007 and 2011 were reviewed using a 16-point AE reporting quality score (AERQS) based on the 2004 CONSORT extension. Multivariable linear regression was used to identify features associated with improved reporting quality. A total of 325 RCTs were reviewed. The mean AERQS was 10.1 on a 16-point scale. The most common items that were poorly reported were the methodology of AE collection (adequately reported in only 10% of studies), the description of AE characteristics leading to withdrawals (15%), and whether AEs are attributed to trial interventions (38%). Even when reported, the methods of AE collection and analysis were highly heterogeneous. The multivariable regression model revealed that industry funding, intercontinental trials, and trials in the metastatic setting were predictors of higher AERQS. The quality of AE reporting did not improve significantly over time and was not better among articles published in journals with a high impact factor. Our findings show that some methodologic aspects of AE collection and analysis were poorly reported. Given the importance of AEs in evaluating new treatments, authors should be encouraged to adhere to the 2004 CONSORT guidelines regarding AE reporting.
AbstractList The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding adverse event (AE) reporting in randomized clinical trials (RCTs). Limited data exist regarding adherence to these guidelines in publications of oncology RCTs.PURPOSEThe Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding adverse event (AE) reporting in randomized clinical trials (RCTs). Limited data exist regarding adherence to these guidelines in publications of oncology RCTs.All phase III RCTs published between 2007 and 2011 were reviewed using a 16-point AE reporting quality score (AERQS) based on the 2004 CONSORT extension. Multivariable linear regression was used to identify features associated with improved reporting quality.METHODSAll phase III RCTs published between 2007 and 2011 were reviewed using a 16-point AE reporting quality score (AERQS) based on the 2004 CONSORT extension. Multivariable linear regression was used to identify features associated with improved reporting quality.A total of 325 RCTs were reviewed. The mean AERQS was 10.1 on a 16-point scale. The most common items that were poorly reported were the methodology of AE collection (adequately reported in only 10% of studies), the description of AE characteristics leading to withdrawals (15%), and whether AEs are attributed to trial interventions (38%). Even when reported, the methods of AE collection and analysis were highly heterogeneous. The multivariable regression model revealed that industry funding, intercontinental trials, and trials in the metastatic setting were predictors of higher AERQS. The quality of AE reporting did not improve significantly over time and was not better among articles published in journals with a high impact factor.RESULTSA total of 325 RCTs were reviewed. The mean AERQS was 10.1 on a 16-point scale. The most common items that were poorly reported were the methodology of AE collection (adequately reported in only 10% of studies), the description of AE characteristics leading to withdrawals (15%), and whether AEs are attributed to trial interventions (38%). Even when reported, the methods of AE collection and analysis were highly heterogeneous. The multivariable regression model revealed that industry funding, intercontinental trials, and trials in the metastatic setting were predictors of higher AERQS. The quality of AE reporting did not improve significantly over time and was not better among articles published in journals with a high impact factor.Our findings show that some methodologic aspects of AE collection and analysis were poorly reported. Given the importance of AEs in evaluating new treatments, authors should be encouraged to adhere to the 2004 CONSORT guidelines regarding AE reporting.CONCLUSIONOur findings show that some methodologic aspects of AE collection and analysis were poorly reported. Given the importance of AEs in evaluating new treatments, authors should be encouraged to adhere to the 2004 CONSORT guidelines regarding AE reporting.
The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding adverse event (AE) reporting in randomized clinical trials (RCTs). Limited data exist regarding adherence to these guidelines in publications of oncology RCTs. All phase III RCTs published between 2007 and 2011 were reviewed using a 16-point AE reporting quality score (AERQS) based on the 2004 CONSORT extension. Multivariable linear regression was used to identify features associated with improved reporting quality. A total of 325 RCTs were reviewed. The mean AERQS was 10.1 on a 16-point scale. The most common items that were poorly reported were the methodology of AE collection (adequately reported in only 10% of studies), the description of AE characteristics leading to withdrawals (15%), and whether AEs are attributed to trial interventions (38%). Even when reported, the methods of AE collection and analysis were highly heterogeneous. The multivariable regression model revealed that industry funding, intercontinental trials, and trials in the metastatic setting were predictors of higher AERQS. The quality of AE reporting did not improve significantly over time and was not better among articles published in journals with a high impact factor. Our findings show that some methodologic aspects of AE collection and analysis were poorly reported. Given the importance of AEs in evaluating new treatments, authors should be encouraged to adhere to the 2004 CONSORT guidelines regarding AE reporting.
Author Chen, Eric X
Péron, Julien
You, Benoit
Maillet, Denis
Gan, Hui K
Author_xml – sequence: 1
  givenname: Julien
  surname: Péron
  fullname: Péron, Julien
  organization: Julien Péron, Denis Maillet, and Benoit You, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite; Julien Péron, Hospices Civils de Lyon; Julien Péron and Benoit You, Université de Lyon, Lyon; Julien Péron, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne; Benoit You, EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, Oullins, France; Hui K. Gan, Joint Austin-Ludwig Oncology Unit, Austin Hospital, Melbourne, Victoria, Australia; Eric X. Chen, Princess Margaret Hospital, University Health Network; and Eric X. Chen, University of Toronto, Toronto, Ontario, Canada
– sequence: 2
  givenname: Denis
  surname: Maillet
  fullname: Maillet, Denis
– sequence: 3
  givenname: Hui K
  surname: Gan
  fullname: Gan, Hui K
– sequence: 4
  givenname: Eric X
  surname: Chen
  fullname: Chen, Eric X
– sequence: 5
  givenname: Benoit
  surname: You
  fullname: You, Benoit
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24062406$$D View this record in MEDLINE/PubMed
BookMark eNpNkE9rGzEQxUVxaBwn95yKjr3YlbSSterNmLRJMTHkz9mMpHGqsqt1pV0H5zv0O1dtHMhhmGHe782DOSOj2EUk5JKzGReMffmxXM8E49VMmlllav6BjLkSeqq1UqN38yk5y_kXY1zWlfpIToVk8381Jn8W_icmjA5p39Hl-vZ-ffdAwe8xZaS4x9jThLsu9SE-0acheGxCxExDpAmi79rwgp66sgwOGtqnAE0uRmgG-O_Jh9xjGxx1UFIS7Use7A5fKRylgrmSsQ_4fE5OtsWOF8c-IY_frh6W19PV-vvNcrGausqofrr1wEELUFJyqJVwNQcAL7m1ym2tsQbZ3DBTdPS6strpucW5to6BrK0RE_L59e4udb8HzP2mDdlh00DEbsgbLqWWpla1KOinIzrYFv1ml0IL6bB5e6H4C6cDeIs
CitedBy_id crossref_primary_10_1111_jebm_70006
crossref_primary_10_1093_asjof_ojae057
crossref_primary_10_1093_annonc_mdw218
crossref_primary_10_1097_MPA_0000000000001234
crossref_primary_10_1007_s40264_018_0680_0
crossref_primary_10_1016_j_jid_2025_02_144
crossref_primary_10_1002_onco_13812
crossref_primary_10_1016_j_critrevonc_2016_08_012
crossref_primary_10_1136_bmjopen_2020_048218
crossref_primary_10_1016_S1470_2045_17_30190_0
crossref_primary_10_1038_leu_2016_374
crossref_primary_10_1177_23800844251357235
crossref_primary_10_1016_j_ajo_2018_07_014
crossref_primary_10_1007_s10637_024_01481_9
crossref_primary_10_1080_08989621_2015_1088788
crossref_primary_10_1002_cam4_4086
crossref_primary_10_1017_neu_2019_24
crossref_primary_10_1016_j_ejca_2018_12_022
crossref_primary_10_1016_j_injury_2024_111326
crossref_primary_10_1200_JCO_18_00145
crossref_primary_10_1016_j_avsg_2024_06_013
crossref_primary_10_1038_bjc_2017_407
crossref_primary_10_1093_ehjqcco_qcz050
crossref_primary_10_1186_s12874_025_02486_5
crossref_primary_10_1016_S1470_2045_16_00038_3
crossref_primary_10_1002_pst_1759
crossref_primary_10_1186_s12885_020_07518_5
crossref_primary_10_1007_s10637_020_00938_x
crossref_primary_10_1007_s11764_025_01778_5
crossref_primary_10_1177_1740774518760565
crossref_primary_10_1038_bjc_2015_55
crossref_primary_10_1038_s41598_022_05861_0
crossref_primary_10_1200_JCO_2014_59_8862
crossref_primary_10_1016_j_rce_2015_05_004
crossref_primary_10_1177_1740774519873883
crossref_primary_10_3390_cancers15225317
crossref_primary_10_1186_s40959_018_0031_4
crossref_primary_10_1016_j_cmi_2019_04_029
crossref_primary_10_1161_CIRCULATIONAHA_118_037585
crossref_primary_10_2147_CEOR_S509349
crossref_primary_10_1002_hon_2875
crossref_primary_10_1002_onco_13940
crossref_primary_10_1016_j_jid_2025_03_015
crossref_primary_10_1001_jamanetworkopen_2019_11519
crossref_primary_10_1016_j_ygyno_2017_11_031
crossref_primary_10_1002_nau_22811
crossref_primary_10_1016_j_respol_2020_104130
crossref_primary_10_1136_bmjopen_2018_024537
crossref_primary_10_3389_fonc_2022_841266
crossref_primary_10_1016_j_esmoop_2025_105796
crossref_primary_10_1016_j_rceng_2015_08_004
crossref_primary_10_1093_annonc_mdv485
crossref_primary_10_1016_j_critrevonc_2017_02_012
crossref_primary_10_1016_j_ejca_2015_08_025
crossref_primary_10_1186_s41073_019_0084_4
crossref_primary_10_1007_s40266_019_00667_8
crossref_primary_10_1016_j_critrevonc_2020_103162
crossref_primary_10_1186_s12874_024_02369_1
crossref_primary_10_1002_cncr_31349
crossref_primary_10_1002_nau_22726
crossref_primary_10_1136_bmjopen_2018_026589
crossref_primary_10_1097_RTI_0000000000000291
crossref_primary_10_1186_s13643_023_02273_7
crossref_primary_10_1002_lary_25195
crossref_primary_10_1038_bjc_2017_427
crossref_primary_10_1002_ijc_32132
crossref_primary_10_1634_theoncologist_2017_0196
crossref_primary_10_1016_S1470_2045_16_00152_2
crossref_primary_10_1016_j_jclinepi_2021_04_020
crossref_primary_10_1093_annonc_mdu489
crossref_primary_10_1080_14740338_2016_1175429
crossref_primary_10_3389_fimmu_2021_736943
crossref_primary_10_1186_s13643_019_1000_1
crossref_primary_10_1186_s40425_018_0426_7
crossref_primary_10_1016_j_ijrobp_2019_08_040
crossref_primary_10_1192_bjp_205_1_82
crossref_primary_10_1093_jmp_jhx032
crossref_primary_10_1093_ndt_gfx216
crossref_primary_10_1183_09059180_00008413
crossref_primary_10_3389_fimmu_2022_874829
crossref_primary_10_1200_JCO_2014_55_2372
crossref_primary_10_1093_jnci_djaa134
crossref_primary_10_1177_03635465251321100
crossref_primary_10_1016_j_jbmt_2024_12_012
crossref_primary_10_1186_s12916_015_0430_4
crossref_primary_10_1136_bmjopen_2020_036875
crossref_primary_10_1080_14796694_2024_2349510
crossref_primary_10_1093_annonc_mdv182
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1200/JCO.2013.49.3981
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
ExternalDocumentID 24062406
Genre Research Support, Non-U.S. Gov't
Systematic Review
Journal Article
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
4.4
53G
5GY
5RE
8F7
AARDX
AAWTL
AAYEP
ABBLC
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C45
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
KQ8
L7B
LSO
MJL
N9A
NPM
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YFH
YQY
7X8
ID FETCH-LOGICAL-c395t-fda1a72a5441a852c81aaad41bb5cfb9b9e06909544ed73b7c76be67bc0a48b92
IEDL.DBID 7X8
ISICitedReferencesCount 94
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000330540700019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1527-7755
IngestDate Mon Jul 21 11:52:31 EDT 2025
Mon Jul 21 05:40:06 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 31
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c395t-fda1a72a5441a852c81aaad41bb5cfb9b9e06909544ed73b7c76be67bc0a48b92
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
PMID 24062406
PQID 1447498582
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1447498582
pubmed_primary_24062406
PublicationCentury 2000
PublicationDate 2013-11-01
PublicationDateYYYYMMDD 2013-11-01
PublicationDate_xml – month: 11
  year: 2013
  text: 2013-11-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2013
SSID ssj0014835
Score 2.4292324
SecondaryResourceType review_article
Snippet The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 3957
SubjectTerms Antineoplastic Agents - adverse effects
Clinical Trials, Phase III as Topic
Drug-Related Side Effects and Adverse Reactions
Guideline Adherence - standards
Guideline Adherence - statistics & numerical data
Guidelines as Topic
Humans
Neoplasms - drug therapy
Randomized Controlled Trials as Topic - standards
Title Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review
URI https://www.ncbi.nlm.nih.gov/pubmed/24062406
https://www.proquest.com/docview/1447498582
Volume 31
WOSCitedRecordID wos000330540700019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEF7xqBAXoLwLRVOp4oRL1o_sLheEoiJUlSRqQ5VbtK9ADtiAA1L4D_3PnfE68gkJqQf7Yq1keT_Pfrsz832MfU2c1z7mJmql2kSp8e1IZ9xFyByklzyxrarK989P0e3K4VD16wO3si6rnMfEKlC7wtIZ-SkSf5Eqmcn4_OExItcoyq7WFhqLbDlBKkOoFsMmi5DKymCTnFuRRWZZnaZEYJz-6PSoriv5lirc9kv-NsGsFprL9f99xQ22VlNMuAiY-MgWfL7JVq7rJPomO-4HuerZCQya7qvyBI6h3whZz7bY3wt3F7oBYVpAp9f93fs1AE0WzqWHSvoJQs4B1z-4fSbFLKqih0kOuAS64n7y6h3Mmy-hcggpYS4wjmOCjvTEgiXwPUHoBpudgYZGYhpCe802u7n8PuhcRbV9Q2QTlU2jsdNci1iTy5mWWWwl11q7lBuT2bFRRnmSSVb43DuRGGFFG7EijG3pVBoV77ClvMj9HgPkZQludI2SyEa84Cptc0vhpu0dEYx99mU-IyP8PSjnoXNfPJejZk722W6Y1tFD0PEYEZmh69M7Rh-wVYJL6EI8ZMtj_F7-M_tgX6aT8umowh3eu_3rf7ZS5K8
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+to+CONSORT+adverse+event+reporting+guidelines+in+randomized+clinical+trials+evaluating+systemic+cancer+therapy%3A+a+systematic+review&rft.jtitle=Journal+of+clinical+oncology&rft.au=P%C3%A9ron%2C+Julien&rft.au=Maillet%2C+Denis&rft.au=Gan%2C+Hui+K&rft.au=Chen%2C+Eric+X&rft.date=2013-11-01&rft.eissn=1527-7755&rft.volume=31&rft.issue=31&rft.spage=3957&rft_id=info:doi/10.1200%2FJCO.2013.49.3981&rft_id=info%3Apmid%2F24062406&rft_id=info%3Apmid%2F24062406&rft.externalDocID=24062406
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon